Enhanced Peptide-Based Vaccination Against Acinetobacter baumannii
Legal Citation
Summary of the Inventive Concept
The present inventive concept relates to improved peptide-based vaccination strategies against Acinetobacter baumannii, overcoming limitations of existing approaches by introducing novel adjuvant effects, targeted immunological responses, and personalized vaccine development.
Background and Problem Solved
The original patent disclosed peptides derived from Acinetobacter baumannii for use in vaccination. However, these peptides may not provide optimal immune responses or may exhibit toxicity issues. The present inventive concept addresses these limitations by introducing modifications to the peptides, adjuvants, and formulations to enhance their efficacy and safety.
Detailed Description of the Inventive Concept
The inventive concept encompasses four primary aspects: 1) peptide modification to enhance adjuvant effects, 2) targeted immunological responses using adjuvants specifically designed to interact with dendritic cells, 3) conjugation of peptides to nanoparticles for improved delivery, and 4) personalized vaccination strategies based on individual genetic profiles. These advancements enable the development of more effective and safer vaccines against Acinetobacter baumannii.
Novelty and Inventive Step
The present inventive concept introduces novel and non-obvious improvements over the original patent, including the modification of peptides to enhance adjuvant effects, the use of targeted adjuvants, and the development of personalized vaccine strategies. These innovations provide a significant enhancement to the existing peptide-based vaccination approach.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include the use of different peptide modifications, adjuvants, or nanoparticle conjugation strategies. Additionally, the personalized vaccine approach could be adapted for use with other pathogens or diseases.
Potential Commercial Applications and Market
The enhanced peptide-based vaccination strategy against Acinetobacter baumannii has significant commercial potential in the infectious disease vaccine market, particularly in hospitals and healthcare settings where antibiotic-resistant strains are prevalent.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/104 |
| C | C07 | C07K14/212 |
| A | A61 | A61K2039/543 |
| A | A61 | A61K2039/55505 |
| A | A61 | A61K2039/55566 |
| G | G01 | G01N2333/22 |
| G | G01 | G01N2469/20 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and immunology, specifically vaccine development for bacterial pathogens, with expertise in peptide engineering, immunological adjuvant design, and personalized medical approaches
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in microbiology or immunology, experienced in protein engineering, vaccine development, and understanding of immunological response mechanisms, familiar with nanoparticle conjugation and adjuvant technologies
Obviousness Rationale
A person skilled in the art would recognize that the PTD's proposed modifications represent predictable variations of the source patent's core vaccine technology. The disclosed enhancements, such as targeted adjuvant design and nanoparticle conjugation, are well-established techniques in vaccine development that would be obvious extensions of the original Acinetobacter baumannii peptide vaccination approach. The personalized vaccination strategy follows directly from known principles of precision medicine and immunological variation.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,615 |
|---|---|
| Title | Peptides derived from Acinetobacter baumannii and their use in vaccination |
| Assignee(s) | Evaxion Biotech A/S |